These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9166935)

  • 1. Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.
    Korst AE; Boven E; van der Sterre ML; Fichtinger-Schepman AM; van der Vijgh WJ
    Br J Cancer; 1997; 75(10):1439-46. PubMed ID: 9166935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice.
    Korst AE; Boven E; van der Sterre ML; Fichtinger-Schepman AM; van der Vijgh WJ
    Eur J Cancer; 1998 Feb; 34(3):412-6. PubMed ID: 9640232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
    Boven E; Verschraagen M; Hulscher TM; Erkelens CA; Hausheer FH; Pinedo HM; van der Vijgh WJ
    Eur J Cancer; 2002 May; 38(8):1148-56. PubMed ID: 12008205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo.
    van der Vijgh WJ; Korst AE
    Eur J Cancer; 1996; 32A Suppl 4():S26-30. PubMed ID: 8976819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients.
    Korst AE; van der Sterre ML; Gall HE; Fichtinger-Schepman AM; Vermorken JB; van der Vijgh WJ
    Clin Cancer Res; 1998 Feb; 4(2):331-6. PubMed ID: 9516919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy-induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues.
    Jarvis IW; Meczes EL; Thomas HD; Edmondson RJ; Veal GJ; Boddy AV; Ottley CJ; Pearson DG; Tilby MJ
    Biochem Pharmacol; 2012 Jan; 83(1):69-77. PubMed ID: 22015635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels.
    Ghazal-Aswad S; Tilby MJ; Lind M; Baily N; Sinha DP; Calvert AH; Newell DR
    Ann Oncol; 1999 Mar; 10(3):329-34. PubMed ID: 10355578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors.
    Korst AE; van der Sterre ML; Eeltink CM; Fichtinger-Schepman AM; Vermorken JB; van der Vijgh WJ
    Clin Cancer Res; 1997 May; 3(5):697-703. PubMed ID: 9815738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
    Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
    Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients.
    Zackrisson AL; Malmström H; Peterson C
    Eur J Clin Pharmacol; 2002 May; 58(2):103-8. PubMed ID: 12012141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitization by interleukin-1alpha of carboplatinum anti-tumor activity against human ovarian (NIH:OVCAR-3) carcinoma cells in vitro and in vivo.
    Wang Z; Lee KB; Reed E; Sinha BK
    Int J Cancer; 1996 Nov; 68(5):583-7. PubMed ID: 8938138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.
    Betticher DC; Anderson H; Ranson M; Meely K; Oster W; Thatcher N
    Br J Cancer; 1995 Dec; 72(6):1551-5. PubMed ID: 8519676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The formation and persistence of carboplatin-DNA adducts in rats.
    Blommaert FA; Michael C; van Dijk-Knijnenburg HC; Schornagel JH; den Engelse L; Fichtinger-Schepman AM
    Cancer Chemother Pharmacol; 1996; 38(3):273-80. PubMed ID: 8646803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice.
    Treskes M; Boven E; van de Loosdrecht AA; Wijffels JF; Cloos J; Peters GJ; Pinedo HM; van der Vijgh WJ
    Eur J Cancer; 1994; 30A(2):183-7. PubMed ID: 8155393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
    Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
    Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of caspase 3 and modulation of some apoptotic genes in human acute promyelocytic leukemia HL-60 cells by carboplatin with amifostine.
    Mirowski M; Rózalski M; Krajewska U; Balcerczak E; Młynarski W; Wierzbicki R
    Pol J Pharmacol; 2003; 55(2):227-34. PubMed ID: 12926551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effects of amifostine (Ethyol) in patients treated with carboplatin.
    Budd GT; Ganapathi R; Bukowski RM; Murthy S
    Eur J Cancer; 1996; 32A Suppl 4():S43-5. PubMed ID: 8976822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group.
    Hilpert F; Stähle A; Tomé O; Burges A; Rossner D; Späthe K; Heilmann V; Richter B; du Bois A;
    Support Care Cancer; 2005 Oct; 13(10):797-805. PubMed ID: 16025262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group.
    Katzenstein HM; Chang KW; Krailo M; Chen Z; Finegold MJ; Rowland J; Reynolds M; Pappo A; London WB; Malogolowkin M;
    Cancer; 2009 Dec; 115(24):5828-35. PubMed ID: 19813275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.